UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 246

Sortiert nach

Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers

BMC neurology, 2024-04, Vol.24 (1), p.116-116, Article 116

2024

Link zum Volltext

Verfügbarkeit prüfen

Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease

Journal of lipid research, 2005-05, Vol.46 (5), p.949-968

2005

Link zum Volltext

Verfügbarkeit prüfen

Targeting Huntingtin Expression in Patients with Huntington’s Disease

The New England journal of medicine, 2019-06, Vol.380 (24), p.2307-2316

2019

Link zum Volltext

Verfügbarkeit prüfen

Acetylcholinesterase and its inhibition in Alzheimer disease

Clinical neuropharmacology, 2004-05, Vol.27 (3), p.141-149

2004

Link zum Volltext

Verfügbarkeit prüfen

Targeting acetylcholinesterase and butyrylcholinesterase in dementia

The international journal of neuropsychopharmacology, 2006-02, Vol.9 (1), p.101-124

2006

Link zum Volltext

Verfügbarkeit prüfen

Translating Antisense Technology into a Treatment for Huntington's Disease

Methods in molecular biology (Clifton, N.J.), 2018-01, Vol.1780, p.497

2018

Link zum Volltext

Verfügbarkeit prüfen

Antidepressant drug development: Focus on triple monoamine reuptake inhibition

Journal of Psychopharmacology, 2015-05, Vol.29 (5), p.526-544

2015

Link zum Volltext

Verfügbarkeit prüfen

Sertraline Treatment of Generalized Social Phobia: A 20-Week, Double-Blind, Placebo-Controlled Study

The American journal of psychiatry, 2001-02, Vol.158 (2), p.275-281

2001

Link zum Volltext

Verfügbarkeit prüfen

Restoration of positive mood states in major depression as a potential drug development target

Journal of psychopharmacology (Oxford), 2014-06, Vol.28 (6), p.527-535

Lane, Roger M

2014

Link zum Volltext

Verfügbarkeit prüfen

Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value

Journal of Alzheimer's disease, 2015-01, Vol.44 (4), p.1039

2015

Link zum Volltext

Verfügbarkeit prüfen

Butyrylcholinesterase genotype and gender influence Alzheimer’s disease phenotype

Alzheimer's & dementia, 2013-03, Vol.9 (2), p.e17-e73

2013

Link zum Volltext

Verfügbarkeit prüfen

Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon 4, and hyperhomocysteinemia in neurodegenerative dementias

Medical hypotheses, 2009-08, Vol.73 (2), p.230

2009

Link zum Volltext

Verfügbarkeit prüfen

Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE ε4, and hyperhomocysteinemia in neurodegenerative dementias

Medical hypotheses, 2009-08, Vol.73 (2), p.230-250

2009

Link zum Volltext

Verfügbarkeit prüfen

Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder

Journal of clinical psychopharmacology, 2002-04, Vol.22 (2), p.190-195

2002

Link zum Volltext

Verfügbarkeit prüfen

SSRI-Induced extrapyramidal side-effects and akathisia: implications for treatment

Journal of psychopharmacology (Oxford), 1998, Vol.12 (2), p.192-214

Lane, Roger M.

1998

Link zum Volltext

Verfügbarkeit prüfen

Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences

Journal of Alzheimer's disease, 2007-07, Vol.11 (4), p.509

2007

Link zum Volltext

Verfügbarkeit prüfen

Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients

Movement disorders, 2008-08, Vol.23 (11), p.1532-1540

2008

Link zum Volltext

Verfügbarkeit prüfen

A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder

Psychopharmacologia, 2004-02, Vol.171 (4), p.390-397

2004

Link zum Volltext

Verfügbarkeit prüfen

Butyrylcholinesterase Kalow variant reduces age‐of‐onset of Alzheimer Disease in apolipoprotein ɛ4 carriers

Alzheimer's & dementia, 2023-12, Vol.19 (S12)

2023

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of dementia rating scales in Parkinson's disease dementia

American journal of Alzheimer's disease and other dementias, 2010-03, Vol.25 (2), p.142

2010

Link zum Volltext

Verfügbarkeit prüfen

Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression

The journal of clinical psychiatry, 2000-11, Vol.61 (11), p.821

2000

Link zum Volltext

Verfügbarkeit prüfen

Prevention of relapse in generalized Social phobia : Results of a 24-week study in responders to 20 weeks of sertraline treatment

Journal of clinical psychopharmacology, 2000-12, Vol.20 (6), p.636-644

2000

Link zum Volltext

Verfügbarkeit prüfen

Butyrylcholinesterase genotype and gender influence Alzheimeras disease phenotype

Alzheimer's & dementia, 2013-03, Vol.9 (2), p.e1-e57

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 246

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(227)
Mit Volltextzugriff
(214)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers

Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease

Targeting Huntingtin Expression in Patients with Huntington’s Disease

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

Acetylcholinesterase and its inhibition in Alzheimer disease

Targeting acetylcholinesterase and butyrylcholinesterase in dementia

Translating Antisense Technology into a Treatment for Huntington's Disease

Antidepressant drug development: Focus on triple monoamine reuptake inhibition

Sertraline Treatment of Generalized Social Phobia: A 20-Week, Double-Blind, Placebo-Controlled Study

Restoration of positive mood states in major depression as a potential drug development target

Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value

Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

Butyrylcholinesterase genotype and gender influence Alzheimer’s disease phenotype

Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon 4, and hyperhomocysteinemia in neurodegenerative dementias

Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE ε4, and hyperhomocysteinemia in neurodegenerative dementias

Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder

SSRI-Induced extrapyramidal side-effects and akathisia: implications for treatment

Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences

Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients

A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder

Butyrylcholinesterase Kalow variant reduces age‐of‐onset of Alzheimer Disease in apolipoprotein ɛ4 carriers

Evaluation of dementia rating scales in Parkinson's disease dementia

Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression

Prevention of relapse in generalized Social phobia : Results of a 24-week study in responders to 20 weeks of sertraline treatment

Butyrylcholinesterase genotype and gender influence Alzheimeras disease phenotype

Suchergebnisse filtern